The 3 years overall survival (OS) rate was 94.2% and the 3 years disease-free survival (DFS) rate was 55.6%; The 3 years OS and DFS of the MALT lymphoma were 97.6% and 64.3% respectively. And the 3 years OS and DFS of the DLBCL were 85.7% and 28.6% respectively.